ArticleDermatology and therapy2025
Clascoterone Stability When Combined with Topical Acne Medications In Vitro.
Article in Dermatology and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionMultimodal topical therapy is recommended by the American Academy of Dermatology for the treatment of acne vulgaris. However, no data are available regarding stability of clascoterone cream 1% when combined with other topical acne medications. The purpose of this study was to evaluate the stability of clascoterone in the presence of tretinoin, adapalene, dapsone, azelaic acid, benzoyl peroxide (BP)/clindamycin, BP/adapalene, and encapsulated BP.
methodsClascoterone cream (0.5 mL) was layered over 0.5 mL of each of the other products on an individual microscope slide and incubated for 8 h at 37 °C. Material from the slides was extracted in methanol and tetrahydrofuran for high-pressure liquid chromatography mass spectrometry (1 mL/min flow rate; 30 °C). Combinations of clascoterone with tretinoin and adapalene were reinjected 12 h after the initial injections to confirm consistent clascoterone detection. Percent recovery of clascoterone for each combination was calculated from a standard curve serially diluted in methanol.
resultsThe mean percentage of clascoterone recovered after incubation with other drugs ranged from 98% to 119%, with 86% recovered following injection of clascoterone alone. Reinjected clascoterone-tretinoin and clascoterone-adapalene samples yielded clascoterone recovery percentages of 97% and 93%, respectively, both within 8% of those recovered from the initial injections.
conclusionsClascoterone demonstrated consistent and reproducible stability in the presence of other topical acne medications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.